Barclays
CTSO icon

Barclays’s Cytosorbents Corp CTSO Stock Holding History

Barclays’s Portfolio CTSO Stock Details CTSO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-5,577
Closed -$10.5K – 5240
2023
Q3 		$10.5K Buy
+5,577
New +$16K ﹤0.01% 4295
2022
Q3 		– Sell
-164
Closed – – 4846
2022
Q2 		$0 Sell
164
-6,530
-98% -$15K ﹤0.01% 5067
2022
Q1 		$22K Sell
6,694
-43,357
-87% -$155K ﹤0.01% 4418
2021
Q4 		$210K Buy
50,051
+32,885
+192% +$185K ﹤0.01% 3548
2021
Q3 		$140K Buy
17,166
+11,221
+189% +$91.2K ﹤0.01% 3769
2021
Q2 		$45K Sell
5,945
-28,399
-83% -$239K ﹤0.01% 4176
2021
Q1 		$299K Buy
34,344
+21,084
+159% +$201K ﹤0.01% 3500
2020
Q4 		$105K Sell
13,260
-5,540
-29% -$46.4K ﹤0.01% 4109
2020
Q3 		$150K Sell
18,800
-10
-0.1% -$90 ﹤0.01% 4028
2020
Q2 		$185K Buy
18,810
+8,698
+86% +$79.9K ﹤0.01% 4123
2020
Q1 		$77K Sell
10,112
-20,509
-67% -$104K ﹤0.01% 4963
2019
Q4 		$118K Buy
30,621
+15,453
+102% +$67.4K ﹤0.01% 5380
2019
Q3 		$76K Sell
15,168
-4,572
-23% -$26.6K ﹤0.01% 5677
2019
Q2 		$130K Sell
19,740
-1,265
-6% -$8.69K ﹤0.01% 5480
2019
Q1 		$159K Buy
21,005
+7,415
+55% +$57.7K ﹤0.01% 4996
2018
Q4 		$109K Buy
13,590
+1,517
+13% +$15.1K ﹤0.01% 4985
2018
Q3 		$155K Buy
12,073
+9,768
+424% +$122K ﹤0.01% 5197
2018
Q2 		$27K Sell
2,305
-5,217
-69% -$49.4K ﹤0.01% 6015
2018
Q1 		$53K Sell
7,522
-25,670
-77% -$194K ﹤0.01% 5864
2017
Q4 		$216K Buy
+33,192
New +$211K ﹤0.01% 4619
2017
Q3 		– Sell
-2
Closed – – 6865
2017
Q2 		$0 Sell
2
-2,555
-100% -$11.2K ﹤0.01% 6676
2017
Q1 		$11K Buy
2,557
+2,507
+5,014% +$14K ﹤0.01% 6038
2016
Q4 		$0 Buy
50
+46
+1,150% +$252 ﹤0.01% 6631
2016
Q3 		$0 Hold
4
– – ﹤0.01% 6626
2016
Q2 		$0 Buy
+4
New +$17 ﹤0.01% 6359
2015
Q3 		– Sell
-2,268
Closed -$14K – 6854
2015
Q2 		$14K Buy
+2,268
New +$15.4K ﹤0.01% 5880

Other funds holding CTSO

GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
SC
Skylands Capital Milwaukee, Wisconsin $763M AUM 26.49% 1-Year Est. Return
AC
Avenir Corporation Alexandria, Virginia $820M AUM 2.4% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Barclays's CTSO Position: Q4 2023 in Review

Barclays sold out of Cytosorbents Corp (CTSO) in Q4 2023, closing a stake of 5,577 shares — an estimated $10.5K sold.

Barclays first reported a position in CTSO in Q2 2015 and held it in 26 quarters. The position peaked at $299K in Q1 2021. 54 funds tracked by Wall St. Rank hold CTSO as of Q4 2023.

  • Barclays reported no remaining Cytosorbents Corp position as of Q4 2023 after selling out during the quarter.
  • Barclays sold 5,577 Cytosorbents Corp shares in Q4 2023, an estimated $10.5K.
  • Barclays first reported a position in Cytosorbents Corp in Q2 2015 and held it in 26 quarters.
  • Barclays's Cytosorbents Corp position peaked at $299K in Q1 2021.
  • 54 funds tracked by Wall St. Rank held Cytosorbents Corp as of Q4 2023.

Based on Barclays's 13F filing for Q4 2023, filed 15 Feb 2024.